The study, in mice and tissue samples, used a protein called TNF that can track down sites in the brain where cancer has spread by recognising a marker found only on tumour blood vessels.
The scientists, from the University of Oxford, found that TNF can home in on these sites and temporarily open the blood-brain barrier (BBB) allowing drugs to pass from the blood system into the tumour.
The BBB acts as a shield that prevents potentially dangerous particles such as bacteria entering the brain. But it’s this same shield that stops cancer drugs reaching tumours that have spread to the brain.
The TNF protein only broke down the BBB in the blood vessels that pass through the tumour, leaving the healthy parts of the brain undamaged by potentially toxic drugs.
The research shows that when TNF is injected into the bloodstream the breast cancer drug herceptin (trastuzumab) which is not normally able to cross the BBB, can reach cancer cells in the brain.
As well as preventing drugs reaching tumours in the brain, the BBB prevents the early diagnosis of the tumour’s spread to the brain as the dyes used to highlight the tumour cannot penetrate the BBB. This new approach will also allow diagnostic dyes to access the tumour and enable earlier diagnosis.
Study author Dr Nicola Sibson, a Cancer Research UK funded scientist at the University of Oxford, said: “Treatments that work very well against the original site of the cancer lose their effectiveness when the cancer spreads to the brain – as these drugs are prevented from getting to the tumour because of the blood-brain-barrier.
“A number of attempts have been made to open up the BBB but they’ve all struggled because they’re either not specific enough to open the BBB only at the site of the tumour or not effective enough to allow the drug across to kill the cancer.”
Dr Kat Arney, science information manager at Cancer Research UK, said: “Getting treatments through the blood-brain barrier remains one of the greatest challenges for cancer researchers. This exciting result points the way to a potentially game-changing moment in finding ways to treat cancers that have spread to the brain. We now need to test this approach in cancer patients to see if it will have the same effect.”
For media enquiries contact the Cancer Research UK press office on 020 3469 8300 or, out of hours, on 07050 264 059.
1. Connell, J. J., et al Selective permeabilization of the blood-brain barrier at sites of metastasis. Journal of the National Cancer Institute. DOI:10.1093/jnci/djt276
Notes to editors
The work is the subject of a patent application under management by Isis Innovation, the technology transfer company of the University of Oxford. Isis Innovation is inviting interest from prospective industry partners to support the translation of the work to the clinic. For commercial and licensing enquiries please contact Isis Innovation at E: email@example.com or T: 01865 614436 or visit W: www.isis-innovation.com for further information.